BRPI0918360A2 - composto, composição farmacêutica e usos de um composto - Google Patents
composto, composição farmacêutica e usos de um compostoInfo
- Publication number
- BRPI0918360A2 BRPI0918360A2 BRPI0918360A BRPI0918360A BRPI0918360A2 BR PI0918360 A2 BRPI0918360 A2 BR PI0918360A2 BR PI0918360 A BRPI0918360 A BR PI0918360A BR PI0918360 A BRPI0918360 A BR PI0918360A BR PI0918360 A2 BRPI0918360 A2 BR PI0918360A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13949208P | 2008-12-19 | 2008-12-19 | |
| PCT/US2009/068496 WO2010080503A1 (en) | 2008-12-19 | 2009-12-17 | Heterocyclic compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0918360A2 true BRPI0918360A2 (pt) | 2017-10-10 |
| BRPI0918360A8 BRPI0918360A8 (pt) | 2017-12-05 |
Family
ID=42316723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0918360A BRPI0918360A8 (pt) | 2008-12-19 | 2009-12-17 | Composto, composição farmacêutica e usos de um composto |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8232273B2 (pt) |
| EP (1) | EP2373163B1 (pt) |
| JP (1) | JP5770102B2 (pt) |
| KR (1) | KR101685718B1 (pt) |
| CN (1) | CN102316733B (pt) |
| AU (1) | AU2009335843A1 (pt) |
| BR (1) | BRPI0918360A8 (pt) |
| CA (1) | CA2747170C (pt) |
| CL (1) | CL2011001485A1 (pt) |
| CO (1) | CO6390075A2 (pt) |
| CR (1) | CR20110388A (pt) |
| DO (1) | DOP2011000199A (pt) |
| EC (1) | ECSP11011213A (pt) |
| ES (1) | ES2544452T3 (pt) |
| IL (1) | IL213596A0 (pt) |
| MX (1) | MX2011006509A (pt) |
| NZ (1) | NZ593537A (pt) |
| PE (1) | PE20120334A1 (pt) |
| RU (1) | RU2525116C2 (pt) |
| SG (1) | SG172259A1 (pt) |
| WO (1) | WO2010080503A1 (pt) |
| ZA (1) | ZA201104467B (pt) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2951295C (en) | 2007-04-16 | 2020-04-28 | Abbvie Inc. | 7-nonsubstituted indole mcl-1 inhibitors |
| NZ593536A (en) | 2008-12-19 | 2013-07-26 | Genentech Inc | Quinoline derivatives and methods of use |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| CA2836669C (en) * | 2011-05-20 | 2019-03-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds as diacylglycerol acyltransferase inhibitors |
| TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8940737B2 (en) | 2011-10-14 | 2015-01-27 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8889675B2 (en) | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| JP5955531B2 (ja) * | 2011-11-07 | 2016-07-20 | 千葉県 | 抗癌剤 |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| CN103515415A (zh) * | 2012-06-26 | 2014-01-15 | 群康科技(深圳)有限公司 | 叠层结构与其制造方法、以及包含其的电子装置 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| CA2879332C (en) * | 2012-08-13 | 2022-08-30 | Abbvie Inc. | 1,2,3,4- tetrahydroisoquinoline-8-carboxamide compounds and their use as apoptosis-inducing agents |
| EP2892534B8 (en) * | 2012-09-06 | 2021-09-15 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AU2013328870A1 (en) * | 2012-10-11 | 2015-02-26 | F. Hoffmann-La Roche Ag | Azaindolines |
| US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| WO2014145852A2 (en) | 2013-03-15 | 2014-09-18 | Knopp Biosciences Llc | Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| FR3008979B1 (fr) * | 2013-07-23 | 2015-07-24 | Servier Lab | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008975A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| IL286427B2 (en) | 2014-01-28 | 2024-08-01 | Mayo Found Medical Education & Res | Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease |
| EP3139942B1 (en) | 2014-05-05 | 2019-12-18 | Bioventures, Llc | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
| WO2016014625A1 (en) | 2014-07-22 | 2016-01-28 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for selectively depleting senescent cells |
| SMT202300362T1 (it) | 2014-09-12 | 2023-11-13 | Biohaven Therapeutics Ltd | Benzoimidazol-1,2-il-ammidi come attivatori di canale kv7 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CN107207553A (zh) * | 2014-12-09 | 2017-09-26 | 艾伯维公司 | Bcl‑xl抑制性化合物和包括其的抗体药物缀合物 |
| CN111620861A (zh) * | 2014-12-09 | 2020-09-04 | 艾伯维公司 | 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物 |
| WO2016131100A1 (en) * | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| US9884841B2 (en) | 2015-04-20 | 2018-02-06 | The Regents Of The University Of Michigan | Small molecule inhibitors of Mcl-1 and uses thereof |
| US10730842B2 (en) | 2015-09-03 | 2020-08-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| AU2016355303B2 (en) * | 2015-11-20 | 2021-10-07 | Mingsight Pharmaceuticals, Inc. | Treatment of autoimmune disease |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| AU2017279550A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
| JP7278208B2 (ja) * | 2016-08-09 | 2023-05-19 | ザ ユニバーシティ オブ ダラム | 合成レチノイド（細胞の調節における） |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
| WO2018092064A1 (en) * | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| CN108186642B (zh) * | 2018-01-11 | 2019-11-08 | 广西师范大学 | 一种协同起作用治疗肺癌的药物组合物 |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| EP3755703B1 (en) | 2018-02-20 | 2022-05-04 | Incyte Corporation | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer |
| US12528810B2 (en) | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| SG11202008030WA (en) | 2018-03-19 | 2020-10-29 | Knopp Biosciences Llc | Kv7 channel activators compositions and methods of use |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| US12084423B2 (en) | 2018-05-18 | 2024-09-10 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AR119494A1 (es) * | 2019-07-29 | 2021-12-22 | Servier Lab | DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS |
| BR112022002059A2 (pt) | 2019-08-06 | 2022-06-07 | Incyte Corp | Formas sólidas de um inibidor de hpk1 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN112079791A (zh) * | 2020-08-21 | 2020-12-15 | 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） | 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用 |
| AU2021386367A1 (en) | 2020-11-24 | 2023-06-22 | Les Laboratoires Servier | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| KR102605163B1 (ko) * | 2021-06-01 | 2023-11-23 | 연세대학교 산학협력단 | 뇌암의 예방 또는 치료용 조성물 |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN114294905B (zh) * | 2021-11-19 | 2023-04-25 | 中粮生物科技股份有限公司 | 利用红外或微波干燥聚羟基脂肪酸酯的方法 |
| AU2023271885A1 (en) | 2022-05-20 | 2024-12-12 | Les Laboratoires Servier | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| US20250387504A1 (en) | 2022-05-20 | 2025-12-25 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| CN119562832A (zh) | 2022-05-20 | 2025-03-04 | 诺华股份有限公司 | Met bcl-xl抑制剂抗体-药物缀合物及其使用方法 |
| WO2024036961A1 (zh) * | 2022-08-19 | 2024-02-22 | 北京三秀生物医药科技有限公司 | 一种抗衰老相关疾病的前药及其使用方法 |
| PY24103486A (es) | 2023-11-22 | 2025-06-06 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| AR134424A1 (es) | 2023-11-22 | 2026-01-14 | Novartis Ag | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos |
| WO2025130875A1 (zh) * | 2023-12-18 | 2025-06-26 | 南京瑞初医药有限公司 | 氮杂环化合物及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3718570A1 (de) * | 1987-06-03 | 1988-12-15 | Boehringer Ingelheim Kg | Benzo- und thieno-3,4-dihydro-1- pyridinylessigsaeurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| WO2001072712A1 (en) * | 2000-03-24 | 2001-10-04 | Cor Therapeutics, Inc. | ISOQUINOLONE INHIBITORS OF FACTOR Xa |
| CZ2003284A3 (cs) * | 2000-08-01 | 2003-09-17 | Ono Pharmaceutical Co., Ltd. | 3,4-Dihydroisochinolinový derivát a farmaceutické činidlo obsahující tento derivát jako účinnou složku |
| US20050124614A1 (en) * | 2002-07-03 | 2005-06-09 | Axys Pharmaceuticals, Inc. | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis |
| WO2005030729A1 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinoline potassium channel inhibitors |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| NZ552397A (en) * | 2004-07-15 | 2011-04-29 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| US7402596B2 (en) * | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| WO2007084391A2 (en) * | 2006-01-18 | 2007-07-26 | Amgen Inc. | Thiazole compounds as protein kinase b ( pkb) inhibitors |
| EP2078004B1 (en) * | 2006-10-31 | 2015-02-25 | Merck Sharp & Dohme Corp. | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| EP2118088B1 (en) * | 2006-12-20 | 2012-05-30 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
| EP2136639B1 (en) * | 2007-04-02 | 2016-03-09 | Evotec AG | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
| CA2951295C (en) * | 2007-04-16 | 2020-04-28 | Abbvie Inc. | 7-nonsubstituted indole mcl-1 inhibitors |
| MY162157A (en) * | 2007-04-16 | 2017-05-31 | Abbott Lab | Substituted indole mcl-1 inhibitors |
| MY150032A (en) * | 2007-07-19 | 2013-11-29 | Merck Sharp & Dohme | Heterocyclic amide compounds as protein kinase inhibitors |
| EP2193127A4 (en) | 2007-09-27 | 2011-09-14 | Inst Medical W & E Hall | BENZOTHIAZOLE COMPOUNDS |
| NZ593536A (en) * | 2008-12-19 | 2013-07-26 | Genentech Inc | Quinoline derivatives and methods of use |
-
2009
- 2009-12-17 WO PCT/US2009/068496 patent/WO2010080503A1/en not_active Ceased
- 2009-12-17 CA CA2747170A patent/CA2747170C/en not_active Expired - Fee Related
- 2009-12-17 MX MX2011006509A patent/MX2011006509A/es active IP Right Grant
- 2009-12-17 SG SG2011044856A patent/SG172259A1/en unknown
- 2009-12-17 EP EP09837920.9A patent/EP2373163B1/en active Active
- 2009-12-17 NZ NZ593537A patent/NZ593537A/xx not_active IP Right Cessation
- 2009-12-17 RU RU2011129776/04A patent/RU2525116C2/ru active
- 2009-12-17 ES ES09837920.9T patent/ES2544452T3/es active Active
- 2009-12-17 US US12/641,141 patent/US8232273B2/en active Active
- 2009-12-17 KR KR1020117016722A patent/KR101685718B1/ko not_active Expired - Fee Related
- 2009-12-17 CN CN200980156732.7A patent/CN102316733B/zh active Active
- 2009-12-17 AU AU2009335843A patent/AU2009335843A1/en not_active Abandoned
- 2009-12-17 JP JP2011542439A patent/JP5770102B2/ja active Active
- 2009-12-17 BR BRPI0918360A patent/BRPI0918360A8/pt not_active Application Discontinuation
- 2009-12-17 PE PE2011001254A patent/PE20120334A1/es not_active Application Discontinuation
-
2011
- 2011-06-15 ZA ZA2011/04467A patent/ZA201104467B/en unknown
- 2011-06-16 IL IL213596A patent/IL213596A0/en unknown
- 2011-06-17 CL CL2011001485A patent/CL2011001485A1/es unknown
- 2011-06-20 DO DO2011000199A patent/DOP2011000199A/es unknown
- 2011-07-06 CO CO11084232A patent/CO6390075A2/es active IP Right Grant
- 2011-07-18 CR CR20110388A patent/CR20110388A/es unknown
- 2011-07-18 EC EC2011011213A patent/ECSP11011213A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8232273B2 (en) | 2012-07-31 |
| ZA201104467B (en) | 2012-10-31 |
| US20100210622A1 (en) | 2010-08-19 |
| JP2012512891A (ja) | 2012-06-07 |
| DOP2011000199A (es) | 2011-10-15 |
| MX2011006509A (es) | 2011-10-19 |
| RU2525116C2 (ru) | 2014-08-10 |
| CA2747170A1 (en) | 2010-07-15 |
| RU2011129776A (ru) | 2013-01-27 |
| PE20120334A1 (es) | 2012-04-16 |
| EP2373163B1 (en) | 2015-06-10 |
| KR101685718B1 (ko) | 2016-12-12 |
| CA2747170C (en) | 2017-07-18 |
| CN102316733A (zh) | 2012-01-11 |
| ES2544452T3 (es) | 2015-08-31 |
| CN102316733B (zh) | 2014-01-01 |
| CO6390075A2 (es) | 2012-02-29 |
| JP5770102B2 (ja) | 2015-08-26 |
| EP2373163A1 (en) | 2011-10-12 |
| SG172259A1 (en) | 2011-07-28 |
| EP2373163A4 (en) | 2012-10-24 |
| NZ593537A (en) | 2013-07-26 |
| AU2009335843A1 (en) | 2011-07-21 |
| CL2011001485A1 (es) | 2012-02-24 |
| BRPI0918360A8 (pt) | 2017-12-05 |
| CR20110388A (es) | 2011-09-09 |
| KR20110102473A (ko) | 2011-09-16 |
| IL213596A0 (en) | 2011-07-31 |
| WO2010080503A1 (en) | 2010-07-15 |
| ECSP11011213A (es) | 2011-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0918360A2 (pt) | composto, composição farmacêutica e usos de um composto | |
| BRPI1016219A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI1008793A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BRPI0919942A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0907562A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0921375A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI1007018A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| BRPI1008906A2 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
| BRPI0917579A2 (pt) | composto, composição farmacêutica, métodos, e, uso de um composto | |
| BRPI0906962A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0906556A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI1009372A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| BRPI0908021A2 (pt) | Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica | |
| BRPI0921879A2 (pt) | composto, composição farmacêutica , e, uso de um composto | |
| BRPI0810696A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BR112013008259A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112013015397A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0917681A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0906937A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI1009757A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| BRPI0915473A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| DK2285413T3 (da) | Farmaceutisk sammensætning | |
| BRPI1007186A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| EP2236149A4 (en) | MEDICAL COMPOSITION | |
| BRPI0919165A2 (pt) | composição farmacêutica,e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: GENENTECH, INC. (US) , THE WALTER AND ELIZA HALL I |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |